REVIEW ARTIKEL: STUDI KOMPARASI EFEKTIVITAS PENGGUNAAN PHOSPHATE BINDER PADA PENGOBATAN PASIEN CHRONIC KIDNEY DISEASE (CKD)

Yunitasya Guspira, Insan Sunan Kurniawan Syah

Abstrak


Chronic Kidney Disease (CKD) atau penyakit ginjal kronis merupakan penyakit yang mengalami kenaikan jumlah kasus serta dianggap permasalahan yang gawat. Kondisi CKD menyebabkan gangguan keseimbangan elektrolit seperti hiperfosfatemia. Hiperfosfatemia didefinisikan sebagai gangguan metabolisme mineral pada pasien CKD. Fosfat adalah jenis mineral yang sering terganggu metabolismenya diantara komplikasi CKD yang perlu menjadi perhatian khusus karena berperan tinggi pada morbiditas dan mortalitas. Tulisan ini bertujuan untuk menelaah perbandingan efektivitas adanya terapi tambahan phosphate binder ke dalam regimen pengobatan CKD. Metode yang digunakan adalah penelaahan beberapa literatur melalui Google Scholar dan Pubmed mengenai literatur atau tulisan yang menjelaskan penambahan phosphate binder pada pasien CKD. Disimpulkan bahwasanya phosphate binder yang paling efektif dengan dilihat dari penurunan kadar fosfat yang signifikan yaitu sevelamer, namun tetap dikembalikan terhadap kondisi individu.
Kata Kunci: Chronic Kidney Disease (CKD), hiperfosfatemia, phosphate binder


Teks Lengkap:

PDF

Referensi


Brunner, & Suddarth. (2013). Buku Ajar Keperawatan Medikal Bedah (8th ed., Vol. 2). EGC.

Chan, S., Au, K., Francis, R. S., Mudge, D. W., Johnson, D. W., & Pillans, P. I. (2017). Phosphate binders in patients with chronic kidney disease. Australian Prescriber, 40(1), 9–14. https://doi.org/10.18773/austprescr.2017.002

Chennasamudram, S. P., Noor, T., & Vasylyeva, T. L. (2013). COMPARISON OF SEVELAMER AND CALCIUM CARBONATE ON ENDOTHELIAL FUNCTION AND INFLAMMATION IN PATIENTS ON PERITONEAL DIALYSIS.

Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A. H., Scialla, J., Wahl, P., Gutiérrez, O. M., Steigerwalt, S., He, J., Schwartz, S., Lo, J., Ojo, A., Sondheimer, J., Hsu, C.-Y., Lash, J., Leonard, M., Kusek, J. W., Feldman, H. I., & Wolf, M. (2011). Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease. http://jama.jamanetwork.com/

Jandaghi, E., Yarmohammadi, M., Ghorbani, R., Jalali, T., Salehani, A., & Khani, P. (2021). Comparison of sevelamer and calcium carbonate in prevention of hypomagnesemia in hemodialysis patients. International Journal of Preventive Medicine, 12(1). https://doi.org/10.4103/ijpvm.IJPVM_464_19

Jüppner, H. (2011). Phosphate and FGF-23. In Kidney International (Vol. 79, Issue SUPPL. 121). Nature Publishing Group. https://doi.org/10.1038/ki.2011.27

Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. In The Lancet (Vol. 398, Issue 10302, pp. 786–802). Elsevier B.V. https://doi.org/10.1016/S0140-6736(21)00519-5

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). (2017). Kidney International Supplements, 7(1), 1–59. https://doi.org/10.1016/j.kisu.2017.04.001

Kementerian Kesehatan RI. (2018). Hasil Utama Riskesdas tahun 2018. Https://Kesmas.Kemkes.Go.Id/Assets/Upload/Dir_519d41d8cd98f00/Files/Hasil-Riskesdas-2018_1274.Pdf.

Kovesdy, C. P., & Quarles, L. D. (2016). FGF23 from bench to bedside. Am J Physiol Renal Physiol, 310, 1168–1174. https://doi.org/10.1152/ajprenal.00606.2015.-There

Luyckx, V. A., Tonelli, M., & Stanifer, J. W. (2018). The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization, 96(6), 414-422C. https://doi.org/10.2471/BLT.17.206441

Martin K, Floege J, & Ketteler M. (2015). Bone and mineral metabolism in chronic kidney disease Comprehensive Clinical Nephrology. (5th ed.). Saunders.

Melisa, Andayani, T. M., & Irijanto, F. (2017). Pengaruh Penggunaan Terapi Sevelamer Terhadap Kualitas Hidup Pasien Hemodialisis yang Dinilai Menggunakan KDQOL SF-36. . Universitas Gadjah Mada.

National Institute for Clinical Excellence. (2013, March 3). . CG157 Hyper-phosphataemia in chronic kidney disease: NICE guideline. Http://Guidance.Nice.Org.Uk/CG157/NICEGuidance/Pdf/English.

Nugroho, P., Marbun, M. B. H., Yunita, B., Astrella, C., Noor, C. A., & Lydia, A. (2021). The Effectiveness and Safety of Calcium Carbonate Use in Chronic Kidney Disease Patients with Normophosphatemia. The Open Urology & Nephrology Journal, 14(1), 13–19. https://doi.org/10.2174/1874303x02114010013

O’Callaghan, C. (2009). Gagal Ginjal Kronik dan Renal Bone Disease (3rd ed.). Erlangga.

Ogata, H., Fukagawa, M., Hirakata, H., Kagimura, T., Fukushima, M., & Akizawa, T. (2021). Effect of Treating Hyperphosphatemia with Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients with Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 325(19), 1946–1954. https://doi.org/10.1001/jama.2021.4807

Patel, L., Bernard, L. M., & Elder, G. J. (2016). Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials. In Clinical Journal of the American Society of Nephrology (Vol. 11, Issue 2, pp. 232–244). American Society of Nephrology. https://doi.org/10.2215/CJN.06800615

Peter, W. L. S., Wazny, L. D., Weinhandl, E., Cardone, K. E., & Hudson, J. Q. (2017). A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? In Drugs (Vol. 77, Issue 11, pp. 1155–1186). Springer International Publishing. https://doi.org/10.1007/s40265-017-0758-5

Phannajit, J., Wonghakaeo, N., Takkavatakarn, K., Asawavichienjinda, T., Praditpornsilpa, K., Eiam-Ong, S., & Susantitaphong, P. (2022). The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials. Journal of Nephrology, 35(2), 473–491. https://doi.org/10.1007/s40620-021-01065-3

Prajapati, V. A., Galani, V. J., & Shah, P. R. (2014). A Comparative Study of Phosphate Binders in Patients with End Stage Kidney Disease Undergoing Hemodialysis. In Saudi J Kidney Dis Transpl (Vol. 25, Issue 3). http://www.sjkdt.org

Russo, D., & Battaglia, Y. (2011). Clinical Significance of FGF-23 in Patients with CKD. International Journal of Nephrology, 2011, 1–5. https://doi.org/10.4061/2011/364890

Soriano, S., Ojeda, R., Rodríguez, M., Almadén, Y., Rodríguez, M., Martín-Malo, A., & Aljama, P. (2013). The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clinical Nephrology, 80(1), 17–22. https://doi.org/10.5414/CN107764

Sudoyo, A. W., Setiyohadi, B., Alwi, I., Simadibrata, M., & Setiati, S. (2009). BUKU AJAR ILMU PENYAKIT DALAM EDISI V (5th ed.). Interna Publishing.

Susanti, E., Wulandari, A., Studi III Analis Kesehatan, P. D., Kesehatan, F., Mohammad Husni Thamrin, U., Kunci, K., & Ginjal Kronik, P. (n.d.). HUBUNGAN KADAR KALSIUM DAN FOSFOR DARAH PADA PENDERITA PENYAKIT GINJAL KRONIK (PGK) DI RUMAH SAKIT GADING PLUIT JAKARTA UTARA. Maret 2019 P-Open Journal System (OJS): Journal.Thamrin.Ac.Id, 5(1). http://journal.thamrin.ac.id/index.php/anakes/issue/view/33

Tatsuzawa, M., Ogawa, R., Ohkubo, A., Shimojima, K., Maeda, K., Echizen, H., & Miyazaki, A. (2016). Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review. Journal of Pharmaceutical Health Care and Sciences, 2(1). https://doi.org/10.1186/s40780-016-0068-1

Wald, R., Rabbat, C. G., Girard, L., Garg, A. X., Tennankore, K., Tyrwhitt, J., Smyth, A., Rathe-Skafel, A., Gao, P., Mazzetti, A., Bosch, J., Yan, A. T., Parfrey, P., Manns, B. J., & Walsh, M. (2017). Two phosphate taRGets in end-stage renal disease trial (TARGET): A randomized controlled trial. Clinical Journal of the American Society of Nephrology, 12(6), 965–973. https://doi.org/10.2215/CJN.10941016

Yaguchi, A., Akahane, K., Tsuchioka, K., Yonekubo, S., Yamamoto, S., Tamai, Y., Tatemichi, S., & Takeda, H. (2019). A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study. BMC Nephrology, 20(1). https://doi.org/10.1186/s12882-019-1655-9

Zhai, C. J., Yang, X. W., Sun, J., & Wang, R. (2015). Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. International Urology and Nephrology, 47(3), 527–535. https://doi.org/10.1007/s11255-014-0876-x

Zhang, C., Wen, J., Li, Z., & Fan, J. (2013). Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: A systematic review. In BMC Nephrology (Vol. 14, Issue 1). https://doi.org/10.1186/1471-2369-14-226




DOI: https://doi.org/10.24198/farmaka.v21i2.46876

DOI (PDF): https://doi.org/10.24198/farmaka.v21i2.46876.g20631

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved